Methods of treating disorders with Group I mGluR antagonists
US6916821B2 · kind B2 · utility
7Cited by
0References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 4, 2003 |
| Grant date | Jul 12, 2005 |
| Priority date | — |
| Expiry date | Jun 27, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.